Amisulpride as a model: clinical effects of a pure dopaminergic agent

Amisulpride is pharmacologically unique because it is a highly selective dopaminergic D2 and D3 dopamine receptor blocker with no other interactions with CNS (central nervous system) receptors (Scatton et al, 1997). The drug was first introduced into clinical practice as an antipsychotic in 1987 and has since been used extensively, with over 600 million patient treatment days recorded (based on IMS data).